Back

Vericiguat and exercise capacity in patients with HFrEF; a prospective randomized study

10 May 2026 (12:30 - 13:15)
Organised by: Logo
Congress Presentation Part of: Vericiguat across the heart failure spectrum: mechanisms, haemodynamics, and clinical outcomes Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Argyrios Ntalianis

Alexandra University Hospital, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
The hemodynamic effect of vericiguat during exercise right heart catheterization in patients with HFrEF
Doctor A. Ntalianis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Real-world use of vericiguat in elderly patients with heart failure: insights from the OPTIMA-HF registry
Doctor S. Giovinazzo (Genoa, IT)
Abstract Slides Video
Presentation thumbnail
Role of vericiguat on renal function decline in patients with worsening heart failure
Doctor G. Armentaro (Catanzaro, IT)
Abstract Slides Video
Presentation thumbnail
Hypotension and outcomes after vericiguat initiation in patients with heart failure and mildly reduced or preserved ejection fraction
Doctor T. Suzuki (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
A study to assess the role of vericiguat in the cardio-pulmonary pathophysiology in worsening heart failure with reduced ejection fraction (REVOLUT- HFrEF)
Doctor A. D'Amato (Rome, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Vericiguat across the heart failure spectrum: mechanisms, haemodynamics, and clinical outcomes

The Event

Event poster

Heart Failure 2026

10 May 2026 12:30 CET
You may be interested in
thumbnail
Congress Presentation
The hemodynamic effect of vericiguat during exercise right heart catheterization in patients with HFrEF
thumbnail
Congress Presentation
A study to assess the role of vericiguat in the cardio-pulmonary pathophysiology in worsening heart failure with reduced ejection fraction (REVOLUT- HFrEF)
thumbnail
Congress Presentation
Initial experience of vericiguat treatment in patients with heart failure and high risk of decompensation.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources